Douglas W. Losordo, MD, the Executive Vice President of Caladrius Biosciences, Inc., provides us with an extensive account of his experiences researching vascular biology and cardiovascular issues in general.
Dr. Losordo has enjoyed an extensive career studying the mechanisms of angiogenesis, tissue repair and regeneration, and specific vascular problems. His company, Caladrius Biosciences, Inc., is a biopharmaceutical company that excels in technology platforms targeted to cardiovascular conditions. In their mission to restore health, the company has made significant contributions to late stage programs for cardiovascular disease.
Dr. Losordo provides an overview of blood vessel regeneration, known as angiogenesis. He gives an in-depth explanation of how cells are injected and the beginning of angiogenesis. The vascular expert goes on to discuss some of their deep experimentation with cells in regard to ischemic tissue and much more.
In an assessment of the biological science industry, Dr. Losordo outlines some of the many regulatory issues that create specific challenges for researchers. And he shares information on a few of his company’s newer programs, such as their refractory angina program that has been selected for accelerated approval. He provides further examples of the kinds of work Caladrius Biosciences, Inc. engages in and shares his thoughts on the important science behind their work.